Avammune Therapeutics Secures $12 Million in Series A Financing

Avammune Therapeutics has successfully raised $12 million (approximately Rs 100 crore) in a Series A financing round. This initiative was co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, managed by Kotak Alternate Asset Managers. IvyCap Ventures also participated, alongside the existing investor, 1Crowd.

Funding Purpose and Pipeline Development

The funding will be directed towards accelerating Avammune’s proprietary pipeline, which focuses on the innate immune system. This includes the development of orally bioavailable small molecules and bolstering the clinical progress of its lead candidate, AVA-NP-695. This candidate is an ENPP1 inhibitor, as stated in a press release from Avammune Therapeutics.

About Avammune Therapeutics

Founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune Therapeutics is a biopharmaceutical company dedicated to discovering small molecule medicines. These medications specifically target the innate immune system for treating cancer and autoimmune disorders. The company’s pipeline addresses various conditions, including Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, gastrointestinal cancers, and several autoimmune disorders.

Lead Assets and Market Insights

Avammune has indicated that its lead asset, an ENPP1 inhibitor, has shown promising anti-tumor activity in multiple preclinical cancer models. It has also been effective in veterinary cancer patients under “compassionate use” scenarios. Additionally, AVA-ADR is considered a potential first-in-class ADAR1 p150 inhibitor, standing out as one of the few ADAR1 inhibitors to demonstrate in vivo efficacy.

Immuno-Oncology Market Growth

Market research indicates that the global immuno-oncology market is valued at around $100 billion and is experiencing rapid growth, with a compound annual growth rate (CAGR) of 17%.